ITS BIO

AffinityImmuno Products

ELISA kits, research antibodies, biosimilars and isotype controls from AffinityImmuno.

EL-1611-181 · 1 / 2

EL-1611-181 image 1

AffinityImmuno · ELISA Kit

Rituximab (Rituxan®) Pharmacokinetic ELISA

Cat.No

EL-1611-181

1X96 wells

Reactivity
Human, mouse, rat
Detection range
100ng/ml - 5ng/ml
Sample type
Serum Plasma
Assay time
2.5 hours
Antigen
Rituximab (Rituxan)
Detection minimum
5ng/ml

Product Overview

This Rituximab (Rituxan®) ELISA kit is designed to measure Rituximab with high specificity and enhanced sensitivity. Rituximab is a chimeric monoclonal antibody used in the treatment of diseases characterized by abnormal or excessive B cells.

INTRODUCTION

Rituximab is a chimeric monoclonal antibody used in the treatment of diseases characterized by abnormal or excessive B cells. Rituximab targets CD20, which is expressed on the surface of B cells, to induce apoptosis in B cells and is used in the treatment of leukemia s and lymphomas, some autoimmune disorders, and organ transplant. A quantitative method for rituximab has been developed and optimized for pharmacokinetic assessment of samples.

The Rituximab ELISA kit is designed to measure Rituximab with high specificity and enhanced sensitivity. The assay design utilizes a pair of antibodies that allows the detection of the whole Rituximab molecule in biological matrices.

PRINCIPLE OF THE ASSAY

This assay employs the sandwich enzyme immunoassay technique. Anti- Rituximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Rituximab present in biological matrices is bound by the immobilized anti- Rituximab antibody. After washing away any unbound substances, enzyme linked anti- Rituximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Rituxan® (domain residing in Fc portion of the Rituxan® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Rituximab present in test samples. The color development is stopped and the intensity of the color is measured.

Rituximab (Rituxan®) Pharmacokinetic ELISA standard curve

Need assistance?
Contact our experts for support and fast quotations.
(주)이츠바이오
07532 서울특별시 강서구 양천로 551-17 한화비즈메트로 1차 812호
T : 02-3462-8658  F : 02-3462-8659
E-mail : info@itsbio.co.kr
ITSBio, Inc.
812, Hanwha Bizmetro A-dong, 551-17 YangcheonRo, Gangseo-Gu, Seoul, 07532, Korea, Republic of
T : +82-2-3462-8658  F : +82-2-3462-8659
E-mail : info@itsbio.co.kr
Privacy Policy|Terms|© 2026 ITS BIO. All rights reserved.
Online Message
Send to info@itsbio.co.kr